Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium sulfadiazine is the sodium salt form of sulfadiazine, a short-acting sulfonamide antibiotic. It functions as a competitive antagonist of para-aminobenzoic acid (PABA), thereby inhibiting the bacterial enzyme dihydropteroate synthase, which is essential for the synthesis of dihydrofolic acid. This inhibition disrupts the production of folic acid, a necessary precursor for bacterial DNA and RNA synthesis, leading to a bacteriostatic effect. It is primarily indicated for the treatment of infections caused by susceptible strains of organisms, including urinary tract infections, chancroid, and nocardiosis, and is used as prophylaxis for rheumatic fever and meningococcal meningitis. In pharmaceutical manufacturing, it is often produced as an injectable generic product for parenteral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfadiazine sodium.